The Medical Tourism Market, estimated at USD 16.51 Bn in 2025, is expected to exhibit a CAGR of 13.4% and reach USD 39.84 Bn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
Increasing prevalence of chronic and acute disease is expected to drive growth of global medical tourism market. According to National Center for Biotechnology Information 2018 report, chronic disease is most prevalent and costly health condition in the U.S. Around 45% of all the Americans suffer from at least one chronic disease including cancer, diabetes, hypertension, heart disease, respiratory diseases, arthritis, and obesity.
For instance, according to the Cancer Research UK, around 17 million new cases of cancer were registered and total 9.6 million deaths occurred due to cancer in 2018, globally. Moreover, the four most common cancers occurring worldwide are lung, female breast, bowel, and prostate cancer.
According to the American Heart Association 2018, 103 million U.S. adults have high blood pressure and 6.5 million people are living with heat failure in U.S.
Furthermore, initiative taken by key player for medical tourism is also expect to boost the market growth. For instance, in October 2019, Apollo BGS Hospitals Mysore launched the first ever Stroke unit on the occasion of World Stroke Day 2019.